MARON
AND MCKENNA et al., ACC/ESC Expert Consensus Document on Hypertrophic
Cardiomyopathy
JACC 2003; 42:
000-000
American
College of Cardiology/European Society of Cardiology Clinical
Expert Consensus Document on Hypertrophic Cardiomyopathy
A
Report of the American College of Cardiology Foundation Task
Force on Clinical Expert Consensus Documents and the European
Society of Cardiology Committee for Practice Guidelines
Introduction
Organization
of committee and evidence review. The Writing Committee consisted
of acknowledged experts in hypertrophic cardiomyopathy (HCM)
representing the American College of Cardiology Foundation
and the European Society of Cardiology. Both the academic
and private practice sectors were represented. The document
was reviewed by 2 official reviewers nominated by the ACCF,
3 official reviewers nominated by the ESC, 12 members of the
ACCF Clinical Electrophysiology Committee, and 4 additional
content reviewers nominated by the Writing Committee. The
document was approved for publication by the ACCF Board of
Trustees in August 2003 and the Board of ESC in July 2003.
This document will be considered current until the Task Force
on Clinical Expert Consensus Documents revises or withdraws
it from distribution. In addition to the references cited
as part of this document, a comprehensive bibliography including
relevant, supplementary references is available on the ACCF
and ESC websites.
Purpose
of this Expert Consensus Document. Hypertrophic cardiomyopathy
is a complex and relatively common genetic cardiac disorder
(about 1:500 in the general adult population) 1
that has been the subject of intense scrutiny and investigation
for over 40 years 2-15.
Hypertrophic cardiomyopathy affects men and women equally
and occurs in many races and countries, although it appears
to be under-diagnosed in women, minorities, and under-served
populations.16-20
Hypertrophic
cardiomyopathy is a particularly common cause of sudden cardiac
death (SCD) in young people (including trained athletes) 21-29
and may cause death and disability in patients of all ages,
although it is also frequently compatible with normal longevity.30-35
Because of its heterogeneous clinical course and expression
7,36-42,
HCM frequently presents uncertainty and represents a management
dilemma to cardiovascular specialists and other practitioners,
particularly those infrequently engaged in the evaluation
of patients with this disease. Furthermore, with the recent
introduction of novel treatment strategies targeting subgroups
of patients with HCM 7,36-42,
controversy is predictable, and difficult questions periodically
arise. Consequently, it is now particularly timely to clarify
and place into perspective those clinical issues relevant
to the rapidly evolving management for HCM.
©
2003 by the American College of Cardiology and the European
Society of Cardiology |
